Endocrine and Gastroenterology
IMS researchers in basic and clinical sciences investigate the complex mechanisms that regulate the gut, liver, and endocrine system — advancing knowledge and improving treatments for conditions such as diabetes, hepatitis B and C, inflammatory bowel disease, obesity, and thyroid disorders.
Our scientists also examine how the body responds when key signaling molecules — essential for coordinating and maintaining vital biological functions — become disrupted. By understanding these processes, we aim to develop more effective strategies for prevention, diagnosis, and treatment.
Search our faculty directory for experts in this field.
Student Research
Highlights
In addition to diabetes and weight loss, GLP-1 drugs are now targeting cardiovascular, kidney and metabolic liver disease, sleep apnea and more.
Sinai Health and University of Toronto researchers have shown a blood test can predict Crohn’s disease years before symptoms appear, opening the doors to early diagnosis and potentially prevention.
This issue explores one of today’s most pressing and evolving areas in medical science: metabolic health.
Viewpoint articles cover topics ranging from the rise of GLP-1 therapies and obesity definitions to the metabolic side effects of psychiatric medications and strategies to address them.
Inflammatory bowel disease is on the rise worldwide. In Canada, the number of cases is predicted to increase by approximately 1.3-fold by 2035.